On May 29th, 2013, GlaxoSmithKline (GSK) announced the acquisition of Okairos in an all-cash deal worth $325 million US. The Okairos acquisition helps complement the pharma giant’s existing vaccine technology and expertise and will enable GSK to continue its work developing the next generation of vaccines.
Inhibitex is a specialty biopharmaceutical company that focuses on the production of therapeutics to treat infectious diseases, specifically the viral infections Shingles and Hepatitis C, as well as Staph bacterial infections, which include…
Bristol-Myers Squibb Company (BMS) announced Tuesday that it had signed an agreement to acquire biopharmaceutical company ZymoGenetics for approximately $885 million, or $9.75 per share in cash.
The New York Times reports that about 75 percent of patients taking telaprevir in combination with existing hepatitis C drugs were essentially cured of the virus, compared to 44 percent on standard therapy alone.
Inovio is developing a universal flu vaccine engineered to prevent several strains of influenza at once.
Vertex Pharmaceuticals has been busy raising cash to prepare for the launch of telaprevir to treat hepatitis C.
In preliminary testing done on chimpanzees chronically infected with the hepatitis C virus, SPC3649 dramatically reduced virus levels with no toxic side effects.
Copyright © 2024 | WordPress Theme by MH Themes